ReviewImmunology2015
The life (and death) of CD4+ CD28(null) T cells in inflammatory diseases.
Review in Immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04012294 (Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept), which is not on this map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept
Who cites it
68 citing papers in PubMed, 105 citations in OpenAlex.
- Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients.PloS one · 2019Trial
- Trial
- Chronic Inflammation and Coronary Microvascular Dysfunction.Reviews in cardiovascular medicine · 2026Review
- Cytomegalovirus Drives the Development of Cytotoxic CD4Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- The pivotal role of immunometabolism in diabetic neuropathy and its potential therapeutic strategies.Frontiers in endocrinology · 2026Review
- A Comprehensive Review: Unraveling the Role of Inflammation in the Etiology of Heart Failure.Heart failure reviews · 2025Review
- Circulating CD4+, CD8+, and double-negative T cells in ischemic stroke and stroke-associated infection: a prospective case-control study.Frontiers in cellular neuroscience · 2025Article
- The origin of autoimmune diseases: is there a role for ancestral HLA-II haplotypes in immune hyperactivity.Frontiers in immunology · 2025Review
- Article
- Infection, inflammation and hepatic encephalopathy from a clinical perspective.Metabolic brain disease · 2024Review
- Are immunosenescent T cells really senescent?Aging cell · 2024Review
- Recent advances in understanding the roles of T cells in atrial fibrillation.NPJ cardiovascular health · 2024Article
- Association between Inflammation and New-Onset Atrial Fibrillation in Acute Coronary Syndromes.Journal of clinical medicine · 2024Review
- Lymphocyte-to-Red Blood Cell Ratio-The Guide Star of Acute Coronary Syndrome Prognosis.Healthcare (Basel, Switzerland) · 2024Article
- Novel T-cell subsets as non-invasive biomarkers of vascular damage along the predialysis stages of chronic kidney disease.Frontiers in medicine · 2024Article
- Blood Immunophenotypes of Idiopathic Pulmonary Fibrosis: Relationship with Disease Severity and Progression.International journal of molecular sciences · 2023Article
- Senescent CD4Clinical rheumatology · 2023Article
- Androgen-Induced Cardiovascular Risk in Polycystic Ovary Syndrome: The Role of T Lymphocytes.Life (Basel, Switzerland) · 2023Review
- An evidence-based debate on epigenetics and immunosenescence in COVID-19.Current research in immunology · 2023Review
- Association of the CD28 markers with the disease activity in systemic lupus erythematosus patients.F1000Research · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Inflammation contributes to the development and perpetuation of several disorders and T lymphocytes orchestrate the inflammatory immune response. Although the role of T cells in inflammation is widely recognized, specific therapies that tackle inflammatory networks in disease are yet to be developed. CD4(+) CD28(null) T cells are a unique subset of helper T lymphocytes that recently shot back into the limelight as potential catalysts of inflammation in several inflammatory disorders such as autoimmunity, atherosclerosis and chronic viral infections. In contrast to conventional helper T cells, CD4(+) CD28(null) T cells have an inbuilt ability to release inflammatory cytokines and cytotoxic molecules that can damage tissues and amplify inflammatory pathways. It comes as no surprise that patients who have high numbers of these cells have more severe disease and poor prognosis. In this review, I provide an overview on the latest advances in the biology of CD4(+) CD28(null) T cells. Understanding the complex functions and dynamics of CD4(+) CD28(null) T cells may open new avenues for therapeutic intervention to prevent progression of inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.